A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides  by Helmerhorst, Eva J et al.
A critical comparison of the hemolytic and fungicidal activities of
cationic antimicrobial peptides
Eva J. Helmerhorst*, Ingrid M. Reijnders, Wim van ’t Hof, Enno C.I. Veerman,
Arie V. Nieuw Amerongen
Academic Centre for Dentistry Amsterdam (ACTA), Department of Oral Biochemistry, Vrije Universiteit, Van der Boechorststraat 7,
1081 BT Amsterdam, The Netherlands
Received 18 December 1998; received in revised form 11 February 1999
Abstract The hemolytic and fungicidal activity of a number of
cationic antimicrobial peptides was investigated. Histatins and
magainins were inactive against human erythrocytes and
Candida albicans cells in phosphate buffered saline, but displayed
strong activity against both cell types when tested in 1 mM
potassium phosphate buffer supplemented with 287 mM glucose.
The HC50/IC50 ratio, indicative of the therapeutic index, was
about 30 for all peptides tested. PGLa was most hemolytic
(HC50 = 0.6 WM) and had the lowest therapeutic index (HC50/
IC50 = 0.5). Susceptibility to hemolysis was shown to increase
with storage duration of the erythrocytes and also significant
differences were found between blood collected from different
individuals. In this report, a sensitive assay is proposed for the
testing of the hemolytic activities of cationic peptides. This assay
detects subtle differences between peptides and allows the
comparison between the hemolytic and fungicidal potency of
cationic peptides.
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1. Introduction
Throughout the plant and animal kingdom numerous cati-
onic peptide antibiotics, such as cecropins [1], defensins [2],
magainins [3] and histatins [4^6] have been discovered which
provide the host with a non-immune ¢rst-line defense system
against invading microorganisms. Because of their strong
growth-inhibitory and microbicidal activity against pathogen-
ic bacteria and yeasts in vitro, these peptides have often been
used as design templates for the development of anti-infec-
tious therapeutics [7^10]. To improve the therapeutic index
of these compounds, antimicrobial activity with minimal cy-
totoxicity towards host cells is needed. As an indication for
this index, the lytic activity against human erythrocytes is
often compared to the antibacterial activity in growth inhibi-
tion assays [11^15]. Based on this comparison it is claimed
that natural magainins, mucosal L-defensins, and cecropins
react selectively with the microbial membrane, because they
are not hemolytic [16^19]. In contrast to the activity of bee
venom melittin, which is often used as a positive control pep-
tide in the hemolytic assays [15,20], the activities of many
cationic peptides is strongly dependent on the ionic strength
[9,21^23]. As isotonic conditions are required to prevent
erythrocytes from spontaneous lysis, hemolytic assays are usu-
ally performed in Tris or phosphate bu¡ered saline (PBS) [11^
15], which for antimicrobial assays are considered to be high
salt bu¡ers. Therefore, it is questionable whether the results of
hemolytic assays that are conducted in such bu¡ers can be
compared properly with the results of antibacterial assays
that are conducted in low ionic strength bu¡ers or broths.
In the present study, the hemolytic and candidacidal activ-
ities of cationic peptides from human and amphibian origin
(histatins and magainins, respectively) and of a number of
designed analogs, derived from histatins, were investigated
in high and low ionic strength bu¡ers. The peptides tested
di¡er in chain length, net peptide charge, hydrophobicity
and amphipathicity, thus allowing the e¡ect of these parame-
ters on peptide activity and selectivity to be investigated. In
Table 1, the sequences of the chemically synthesized peptides
used in this study are listed. Histatin 5 is a human salivary
peptide, dhvar1^dhvar5 are analogs of residues 11^24, the
fungicidal domain of histatin 5, located at its C-terminus.
Dhvar1 and dhvar2 were designed to exhibit improved am-
phipathicity in an K-helix [9], dhvar3 and dhvar4 are derived
from dhvar1 and dhvar2, respectively, by substitution of the
negatively charged glutamic acid (E) by a lysine (K), which
yielded a net increase in positive charge of two units. The
sequestration of hydrophobic and hydrophilic amino acids
perpendicular to the axis of the K-helix was quanti¢ed by
calculating the mean hydrophobic moment per residue (W),
with the angle (N) between amino acid side chains set at
100‡ [24]. According to this calculation, histatin 5 is only
weakly amphipathic having a W of 0.091. Dhvar1^dhvar4,
PGLa, and magainin 2 have mean hydrophobic moments
per residue ranging from 0.260 to 0.441 demonstrating the
amphipathic character of these peptides. Dhvar5 was designed
to have a minimal W perpendicular to the helix (W= 0.064). In
contrast to the other peptides, dhvar5 can adopt a segmentally
amphipathic K-helix with a hydrophobic N-terminus and a
hydrophilic C-terminus. The mean hydrophobicity per residue
was calculated using the consensus scale for hydrophobicity
[24]. All peptides were positively charged at neutral pH, ex-
cept dcysSA, the N-terminal 14 residue sequence of cystatin
SA, which was used as a negative control peptide. At neutral
pH, and upon interaction with the lipophilic inside of the
phospholipid bilayer, the histidine side chains may be either
positively charged or uncharged, which dramatically changes
the charge of histatin 5 as it contains seven histidine residues.
It was found that at low ionic strength, in contrast to in
PBS, subtle di¡erences in activity between peptides are detect-
able. Using this sensitive assay, the hemolytic and the fungi-
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cidal properties of cationic peptides have been compared as a
more accurate measure for their therapeutic index.
2. Materials and methods
Peptides were chemically synthesized as described previously [25]
using the T-bag method adapted for 9-£uorenylmethoxycarbonyl
(Fmoc) chemistry. In brief, p-benzyloxybenzyl alcohol resins, with
the ¢rst N-Fmoc-protected amino acids already attached, were in-
cluded inside the T-bags. The coupling reactions were performed in
N,N-dimethylformamide. After completion of the sequence, cleavage
from the resin and simultaneous side chain deprotection was achieved
with a mixture of 5% thioanisole, 5% phenol, 5% water and 85%
tri£uoroacetic acid. Purity analysis was performed by reversed phase
HPLC, and revealed one major peak with only slight contaminations
(6 5%). Chemically synthesized PGLa and magainin 2 were kindly
provided by H.V. Westerho¡ (Department of Microbial Physiology,
Vrije Universiteit, Amsterdam, The Netherlands) and B.J. Appelmelk
(Department of Medical Microbiology, Vrije Universiteit, Amster-
dam, The Netherlands), respectively. All peptides were dissolved in
10 mM PPB (potassium phosphate bu¡er, pH 7.0) to 2 mg/ml and
stored at 320‡C. The ¢nal pH of the stock solution was 6.0.
Human erythrocytes from four healthy individuals were collected in
vacuum tubes containing heparin (¢nal concentration 20.4 U/ml) or
citrate (¢nal concentration 0.129 M) as anti-coagulant. The study was
approved by the medical ethics committee of the Vrije Universiteit,
and informed consent was obtained from all individuals. The eryth-
rocytes were harvested by centrifugation for 10 min at 2000Ug at
+20‡C, and washed three times in PBS (9 mM sodium phosphate,
pH 7.0 in 150 mM NaCl). To the pellet PBS was added to yield a
20% (v/v) erythrocytes/PBS suspension. This cell suspension was used
either directly or stored for 3 weeks at 4‡C. In the latter case the cells
were washed once in PBS to clear the supernatant from hemoglobin
released from lysed erythrocytes during the period of storage. The
20% suspension was diluted 1:20 in PBS or in IGP (isotonic glucose
phosphate bu¡er, 1 mM PPB, pH 7.0, supplemented with 287 mM
glucose as an osmoprotectant) and from this suspension 100 Wl was
added in duplicate to 100 Wl of a two-fold serial dilution series of
peptide in the same bu¡er in a 96-well V-bottomed microtiter plate
(Greiner, Recklinghausen, Germany). Total hemolysis was achieved
with 1% Tween-20. The plates were incubated for 1 h at 37‡C and
then centrifuged for 5 min at 1500Ug at +20‡C. Of the supernatant
£uid 150 Wl was transferred to a £at-bottom low a⁄nity microtiter
plate (Greiner), and the absorbance was measured at 450 nm. The
percentage hemolysis was calculated by: [(A450 of the peptide treated
sample3A450 of bu¡er treated sample)/(A450 of Tween-20 treated
sample3A450 of bu¡er treated sample)]U100%, and the HC50 values,
which represent the concentrations of peptide at which 50% hemolysis
was observed, were determined.
Candida albicans (ATCC 10231) was stored on glycerol at 380‡C
and cultured on Sabouraud dextrose agar (Oxoid, Hampshire, UK)
for 48 h at 30‡C. Several colonies were picked from plate and sus-
pended in PBS or IGP bu¡er to 2U107 colony forming units (CFU)/
ml. Of this suspension 100 Wl was added in duplicate to 100 Wl of a
two-fold serial dilution series of peptide in the same bu¡er in a V-
bottom microtiter plate (Greiner). After 1 h of incubation, 50 Wl from
selected wells was diluted in 9 ml of PBS and 25 Wl was plated on
Sabouraud dextrose agar. After 48 h of incubation at 30‡C, the per-
centage killing was determined by: [13(number of viable counts of
the peptide treated sample/mean number of viable counts in three
bu¡er treated samples)]U100%, and the IC50 values, which represent
the concentrations of peptide at which 50% of the yeast inoculum was
killed, were determined.
Statistical analyses were performed using the SPPS/PC+ Statistical
Software Package, version 6.0 for Windows (SPPS Inc., Chicago, IL,
USA). The e¡ects of storage duration and anti-coagulant on hemol-
ysis (Table 4) were both analyzed by one-way ANOVA with ‘peptide
treatment’ as covariant. Comparison between the susceptibility of
erythrocytes from di¡erent individuals or between the hemolytic ac-
tivity of di¡erent peptides (Table 3) was carried out by a one-way
ANOVA, with ‘peptide treatment’ or ‘individual’ as covariant, respec-
tively, followed by Wilcoxon matched-pairs signed rank tests when
appropriate. Levels of signi¢cance were set at P6 0.05.
3. Results and discussion
The hemolytic activity of membrane-active antimicrobial
peptides against human erythrocytes is often used as a meas-
ure for their cytotoxicity and to estimate their therapeutic
index [11^15]. Based on the absence or the presence of hemo-
lytic activity, these peptides are classi¢ed as peptide antibiotics
or peptide venoms, respectively [16]. In the present study we
show that the hemolytic properties of cationic peptides are
strongly dependent on the conditions under which the hemo-
lytic assay is performed, such as the ionic strength of the
incubation bu¡er, the freshness of the erythrocytes and even
on individual di¡erences in blood group antigens.
The killing activities of histatins and magainins against C.
albicans, measured by the loss in CFU/ml by plating on agar,
were negligible in PBS, which is considered a high ionic
strength bu¡er in candidacidal assays. Only at the highest
test concentrations of dhvar3, dhvar4 and dhvar5 the viable
counts were reduced by 10%, 25% and 90%, respectively (Fig.
1). Likewise, no hemolytic activity against human erythro-
cytes, measured by hemoglobin release, was observed, not
even at the highest peptide concentrations. In contrast,
when the experiments were conducted in IGP, all peptides
were both fungicidal and hemolytic, the negative control pep-
tide dcysSA excepted (Fig. 2). In bu¡er containing sorbitol
instead of glucose, similar results were obtained (data not
shown).
Table 1
Some physical characteristics of the peptides used in this study
Peptide Amino acid sequence Wa Hb Net charge at neutral pHc
Histatin 5 DSHAKRHHGYKRKFHEKHHSHRGY 0.091 30.547 5+/12+d
Dhvar1 KRLFKELKFSLRKY 0.436 30.426 5+
Dhvar2 KRLFKELLFSLRKY 0.425 30.310 4+
Dhvar3 KRLFKKLKFSLRKY 0.441 30.461 7+
Dhvar4 KRLFKKLLFSLRKY 0.439 30.344 6+
Dhvar5 LLLFLLKKRKKRKY 0.064 30.410 7+
PGLa GMASKAGAIAGKIAKVALKAL-a 0.260 +0.042 5+
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS 0.286 30.036 3+/4+d
DcysSA WSPQEEDRIIEGGI 0.214 30.176 33
aW : mean hydrophobic moment per residue of the peptide in K-helical conformation [24].
bH : mean hydrophobicity calculated from the sum of hydrophobicity values [24].
cThe net charge was calculated by the number of (K+R)3(E+D). In PGLa, the positive charge at the N-terminus was not compensated by a
negative charge at the C-terminus, due to amidation, thus increasing the net peptide charge by 1 unit.
dDepending on the charge of histidine (pKa = 6.0).
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These results show that a series of peptides, including mag-
ainins and histatins, that are generally classi¢ed as peptide
antibiotics based on the absence of hemolytic activity in
PBS, do display hemolytic activity when tested under low
ionic strength conditions. Based on the absence of hemolysis
in PBS, it has been suggested that the abundance of negatively
charged sialic acids on the erythrocytes, which are about 80 Aî
away from the red blood cell surface, would protect the cells
against lysis by neutralizing the peptides [18]. We show here
that this argument does not apply when the sensitivity of the
assay is increased. With respect to ionic strength dependence,
it has been reported that even the hemolytic activity of me-
littin, which is hemolytic in PBS and is classi¢ed as a peptide
venom, is inhibited when the phosphate concentration is
raised to 500 mM [26]. This and our ¢ndings suggest that
the peptide-erythrocyte interaction is governed by electrostatic
interactions.
The hemolytic activity of cationic peptides in PBS is often
compared to the antibacterial activity, measured as growth
inhibition in low ionic strength broth, e.g. Mu«ller-Hinton
broth [27]. Besides the fact that the incubation bu¡ers and
the incubation times di¡er, the two assays measure di¡erent
properties, namely the membrane perturbing and growth in-
hibitory activity, respectively, which hampers a proper com-
parison between the outcomes. In the present study, the fun-
gicidal and hemolytic activities are compared after the same
incubation time and in the same bu¡er. Assuming that both
killing and hemolysis are the ¢nal consequence of peptide
binding, we expressed the selectivity of the peptides for the
di¡erent cell types as the ratio of the HC50 and IC50 values
(Table 2). For all cationic peptides, except for PGLa, the
HC50 values were higher than the IC50 values. The mean
HC50/IC50 of the remaining seven peptides was 34 þ 15, indi-
cating that histatins and magainin 2, but not PGLa, express
Fig. 1. Fungicidal activities (A for naturally occurring peptides and control, B for designed variants) and hemolytic activities (C for naturally
occurring peptides and control, D for designed variants) in PBS. C. albicans cells (107 CFU/ml) were incubated for 1 h at 37‡C with a two-
fold serial dilution series of peptide. Viable counts were determined by plating on Sabouraud agar. Human erythrocytes (¢nal concentration
0.5%) were incubated for 1 h at 37‡C with a two-fold dilution series of peptide. Hemolysis was determined by measurement of the OD450 of
the supernatant and compared to hemolysis achieved with 1% Tween-20. Values represent the mean of duplicate experiments þ S.D. (n = 2).
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Fig. 2. Fungicidal activities (A for naturally occurring peptides and control, B for designed variants) and hemolytic activities (C for naturally
occurring peptides and control, D for designed variants) in IGP bu¡er. See the legend of Fig. 1 for experimental details.
Table 2
Fungicidal and hemolytic activities of cationic peptides in low and high ionic strength bu¡ers
In IGPa In PBSb
IC50 (WM)c HC50 (WM)d HC50/IC50 IC50 (WM) HC50 (WM) HC50/IC50
Histatin 5 2.5 þ 1.5e 39 þ 1.5 16 s 66 s 66 n.d.f
Dhvar1 1.3 þ 0.1 36 þ 4.0 28 s 108 s 108 n.d.
Dhvar2 1.6 þ 0.1 59 þ 0.1 37 s 109 s 109 n.d.
Dhvar3 0.4 þ 0.1 20 þ 2.5 50 s 108 s 108 n.d.
Dhvar4 0.9 þ 0.3 23 þ 2.0 26 s 109 s 109 n.d.
Dhvar5 0.5 þ 0.1 29 þ 2.5 58 50 þ 4.1 s 108 n.d.
PGLa 1.1 þ 0.1 0.6 þ 0.1 0.5 s 102 s 102 n.d.
Magainin 2 0.3 þ 0.1 7.2 þ 3.4 24 s 81 s 81 n.d.
DcysSA s 123 s 123 n.d. s 123 s 123 n.d.
aIGP (low ionic strength bu¡er): 1 mM potassium phosphate, pH 7.0, supplemented with 287 mM glucose.
bPBS (high ionic strength bu¡er): 9 mM sodium phosphate bu¡er, pH 7.0, supplemented with 150 mM NaCl.
cIC50 : concentration of peptide which gives 50% reduction in viable counts of C. albicans cells compared to bu¡er treatment.
dHC50 : concentration of peptide which gives 50% hemolysis of human erythrocytes compared to Tween-20 treatment.
eValues represent the mean of duplicate experiments þ S.D. (n = 2).
f n.d.: not calculated.
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selectivity for the fungal cell over the erythrocyte. In the case
of PGLa the poor selectivity is the result of a high activity
against the erythrocytes rather than a low activity against the
fungal cell.
When the peptides were ranked according to their hemo-
lytic activities, the following order was found: PGLasmagai-
nin 2s all histatin variants. Interestingly, PGLa has the high-
est mean hydrophobicity value (+0.042), followed by
magainin 2 (30.036), followed by the histatins (30.310 to
30.547). No correlation was found between the hemolytic
activity and mean amphipathicity per residue (W) or the net
peptide charge. This is in agreement with studies of Kiyota et
al. [28] and Mor et al. [29] who found a positive correlation
between the hydropathic index of peptides and their hemolytic
potential. Also, the results of structure-activity studies on
model peptides derived from magainins show that with an
increase in peptide hydrophobicity the degree of speci¢city
decreases [19]. It is believed that although electrostatic inter-
actions determine the initial attraction, membranes composed
of zwitterionic phospholipids such as the outer lea£et of the
erythrocyte would favor hydrophobic interactions allowing a
deeper insertion and a stronger interaction of the peptide with
lipophilic membrane components leading to e⁄cient lysis [30].
To assess the in£uence of anti-coagulant and storage dura-
tion on the susceptibility of human erythrocytes to lysis, blood
was collected in tubes containing either heparin or citrate as
the anti-coagulant, and tested both directly and after 3 weeks
of storage at 4‡C (Table 3). Statistical analysis of the data
revealed that there are no signi¢cant di¡erences between hep-
arin and citrate blood tested either after 0 or after 21 days of
storage at 4‡C. In contrast, storage itself caused a signi¢cant
increase in the susceptibility to hemolysis, as shown by the
decrease in HC50 values (P6 0.0005 for both heparin and
citrate blood). Only PGLa was equally active against fresh
erythrocytes and erythrocytes stored for 3 weeks (mean
HC50 value 0.6 þ 0.1 WM). The mean ratio [HC50 (erythrocytes
tested at t = 0)/HC50 (erythrocytes tested at t = 21 days)] þ S.D.
for the remaining seven cationic peptides was 9.7 þ 6.6 for
heparin blood and 10.9 þ 6.9 for citrate blood, indicating
that storage for 3 weeks at 4‡C increases the susceptibility
of red blood cells to hemolysis approximately 10-fold. This
might be explained by a time-dependent decrease of ATP
levels in the erythrocyte. Hemolysis by membrane active pep-
tides is most likely the result of perturbation of the lipid
bilayer followed by colloid osmotic lysis [26]. It is conceivable
that fresh erythrocytes, having the ability to regulate their
volume by protein pumps, would be able to counteract small
disruptions in the cellular membrane [31]. This energy-de-
pendent restoration mechanism might be lost upon long-
term storage.
To assess whether individual di¡erences in antigen expres-
sion on red blood cells in£uence the susceptibility to hemol-
Table 3
In£uence of anti-coagulant and storage duration of erythrocytes on the susceptibility to lysis by cationic antimicrobial peptides
Peptide HC50 (WM)a
Heparin bloodb Citrate bloodc
t = 0 days t = 21 days t = 0 days t = 21 days
Histatin 5 39 þ 1.5 9.0 þ 1.0 38 þ 2.0 15 þ 4.0
Dhvar1 36 þ 4.0 5.6 þ 0.6 51 þ 9.0 4.3 þ 0.8
Dhvar2 59 þ 0.1 2.8 þ 0.8 59 þ 1.0 5.7 þ 0.3
Dhvar3 20 þ 2.5 2.4 þ 0.4 25 þ 2.0 3.0 þ 0.1
Dhvar4 23 þ 2.0 3.4 þ 0.6 30 þ 2.0 3.0 þ 0.1
Dhvar5 29 þ 2.5 1.7 þ 0.2 38 þ 2.0 1.5 þ 0.1
PGLa 0.6 þ 0.1 0.5 þ 0.1 0.7 þ 0.1 0.6 þ 0.1
Magainin 2 7.2 þ 3.4 2.2 þ 0.8 7.5 þ 0.5 0.5 þ 0.1
DcysSA s 123 68 þ 7.5 s 123 98 þ 23
aConcentration of peptide at which 50% hemolysis compared to Tween-20 treatment was observed. Values represent the mean of duplicate ex-
periments þ S.D. (n = 2).
bBlood collected in heparin-containing tubes.
cBlood collected in citrate-containing tubes.
Table 4
In£uence of individual di¡erences in the susceptibility of freshly collected erythrocytes to hemolysis by cationic antimicrobial peptides
Peptide HC50 (WM)a
Individual 1 Individual 2 Individual 3 Individual 4
Histatin 5 49 þ 9.0 s 66 36 þ 4.0 39 þ 1.5 X
Dhvar1 34 þ 24 89 þ 20 58 þ 8.0 36 þ 4.0 0.463
Dhvar2 89 þ 12 s 108 73 þ 2.0 59 þ 0.1 0.012b
Dhvar3 51 þ 21 83 þ 13 35 þ 3.0 20 þ 2.5 0.866
Dhvar4 42 þ 12 58 þ 2.0 35 þ 3.0 23 þ 2.0 0.018c
Dhvar5 58 þ 23 99 þ 10 65 þ 15 29 þ 2.5 0.141
PGLa 0.6 þ 01 0.6 þ 01 0.6 þ 0.1 0.6 þ 0.1 0.012c
Magainin 2 19 þ 1.0 17 þ 1.0 8.0 þ 0.1 7.2 þ 3.4 0.012c
DcysSA s 123 s 123 s 123 s 123 n.d.d
aConcentration of peptide at which 50% hemolysis compared to Tween-20 treatment was observed. Values represent the mean of duplicate ex-
periments þ S.D. (n = 2). Individuals 1^4 express blood groups A, B, AB and O antigens, respectively. Right-hand column: analysis of variance
(P values) of the HC50 values of a number of peptides against human erythrocytes.
bHC50 value of the peptide is signi¢cantly higher than that of histatin 5.
cHC50 values of the peptide is signi¢cantly lower that of histatin 5.
dn.d.: not done.
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ysis, blood from four healthy subjects was collected, and
tested in a hemolytic assay in IGP bu¡er (Table 4). Statistical
analysis showed a signi¢cant inter-individual di¡erence in
HC50 values (P6 0.005). There were no di¡erences between
individual 1 and individual 3 (P = 0.25), while the HC50 values
for individual 2 were signi¢cantly higher than for individuals
1 and 3 (P = 0.0019 and P = 0.0010, respectively), and the
HC50 values for individual 4 were signi¢cantly lower than
for individuals 1 and 3 (P = 0.0070 and P = 0.0041, respec-
tively). It is worth noting that all four individuals tested had
di¡erent blood groups according to the ABO classi¢cation
system, individuals 1^4 had blood group A, B, AB, and O,
respectively. One might speculate that the glycosylation pat-
tern of erythrocyte surface antigens of e.g. the ABO system or
Lewis antigens might in£uence the accessibility of the lipid
bilayer, either by binding the peptides or by steric hindrance,
thus determining the inter-individual di¡erences in hemolytic
susceptibility found in vitro.
To compare the HC50 values between peptides, the data
from Table 4 were analyzed using ‘individual’ as covariant.
Table 4 shows the P values of analysis of variance for com-
parison with histatin 5. These data demonstrate that histatin
variant dhvar2 is even signi¢cantly less hemolytic than histatin
5, whereas it exhibits strongly enhanced antibacterial activity
[9], demonstrating that improvement of antibacterial activity
is possible without the concomitant increase in hemolytic ac-
tivity.
Summarizing, in a sensitive hemolytic assay, conducted at
low ionic strength isotonic conditions, subtle di¡erences be-
tween peptides are detectable, which are undetectable in PBS.
Our results emphasize that erroneous conclusions on the cell
selectivity of these peptides can be drawn when the antimicro-
bial and hemolytic assays are not conducted in the same bu¡-
ers. The relative hemolytic activity of a designed analog com-
pared to that of a naturally occurring reference peptide is
probably the best predictor for clinical cytotoxicity. As none
of the designed histatin analogs were markedly more hemo-
lytic than the naturally occurring histatin 5, these peptides
might be expected to be safe candidates for antifungal treat-
ment of super¢cial yeast infections.
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